Group 1 - The overall vaccine sector is under pressure, with Jindike facing continued losses as indicated in its 2025 performance forecast [1] - For the first nine months of 2025, Jindike reported an operating income of 74.66 million yuan, a year-on-year increase of 91.93%, but a net profit attributable to the parent company of -86.47 million yuan, a decrease of 61.74% year-on-year, reflecting significant loss pressure [1] - The decline in vaccination willingness and weak demand are factors impacting the industry, placing Jindike in a challenging adjustment period [1] Group 2 - On February 24, the first trading day after the holiday, the vaccine sector showed overall weak performance, influenced by factors such as reduced demand for HPV vaccines and inventory backlog, which negatively affected Jindike [2] - In contrast, other areas within the pharmaceutical sector, such as innovative drugs and CXO, are experiencing a recovery, while the vaccine sub-sector is clearly under pressure [2] Group 3 - Recently, Jindike's stock price has shown a volatile downward trend, with a single-day drop of 2.51% on February 26, closing at 19.45 yuan, with a trading volume of 19.57 million yuan and a net outflow of 248,500 yuan from main funds [1] - As of February 27, the stock price slightly increased by 0.26% to 19.50 yuan, but the cumulative decline over the past five days was 1.56%, and it has decreased by 3.61% year-to-date [1] - The financing balance has been continuously declining, with a reduction of 6 million yuan over the past five days, representing an 18.62% decrease, indicating a weak market liquidity [1]